Becton Dickinson and : Q1 2021 Earnings Info Graphic
February 11, 2021 at 01:11 pm EST
Share
Creating value through fulfilling our purpose
"BD's strong revenue and EPS growth reflect solid execution across the company and positive momentum to start fiscal 2021," said Tom Polen, CEO and president of BD. "While the market continues to be dynamic with the COVID-19 pandemic, BD has emerged as an essential partner to help the world respond to the COVID-19 pandemic from diagnostics to devices used in treatment to injection devices for vaccines and real-time surveillance and reporting. I'm proud of the worldwide BD team for their COVID-19 response efforts and support of healthcare providers around the world. We are focused on driving our BD 2025 Grow-Simplify-Empower strategic initiatives which include bringing new and exciting innovations to the health care markets, expanding access globally and creating value for our shareholders. To that end, we continue to make solid progress."
-Tom Polen, CEO and PresidentBD earned a perfect score on the Human Rights Campaign Corporate Equality Index for the
4
th
consecutive yearBD recognized for gender equality by Bloomberg for the
2nd
year in a row
Nearly tripling3 our BD Veritor™ Systems to
Our innovation, scale and execution enable us to be an essential partner in responding to the global COVID-19 pandemic
1B injection devices to enable COVID-19 vaccinations4
>70,000
1. Reflects currency-neutral revenue growth for the three-month period ended December 31, 2020 compared to the comparable period in 2019 on a year-over-year basis.
2. Reflects adjusted non-GAAP earnings per share, which excludes, among other things, the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); integration, restructuring and transaction costs.
3. Represents the number of BD Veritor™ analyzers added since the beginning of the COVID-19 pandemic.
4. As of December 2020.
These materials include non-GAAP financial measures. A reconciliation to the comparable GAAP measures can be found in our earnings release including the financial schedules and financial supplements, posted on the "Investors" section of the BD.com website. This document contains forward-looking statements and it's possible that actual results could differ from our expectations. Factors that could cause such differences appear in our first quarter of fiscal 2021 earnings release furnished as an exhibit to the Form 8-K that BD filed on February 4, 2021 with the SEC, and in our recent SEC filings.
Attachments
Original document
Permalink
Disclaimer
BD - Becton, Dickinson and Company published this content on 04 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 February 2021 18:10:05 UTC.
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).